Cardiovascular signs originate due to the activity of the cardiac glycosides
. Their mechanism of action is based on the inhibition of sodium-potassium pump (Na/K-ATPase), resulting in depletion of intracellular potassium and increased level of intracellular sodium.
help improve symptoms of congestive heart failure, but do not necessarily lower the rate of patient mortality (Adams & Holland, 2011).
With the exception of animal-derived, digoxin-specific Fab antibodies to inactivate ingested plant-derived cardiac glycosides
and physostigmine to reverse plant toxin-induced central anticholinergic syndromes, there are few remaining effective antidotes for most plant toxins.
Interestingly, these events occur at nontoxic (nanomolar) concentrations, well below the concentrations of any reported toxic complications encountered with therapeutic cardiac glycoside
(5,6,7,8,9,10,11,12,13) Page stated that cardiac glycosides
specifically inhibit the active transport of Na+ out of the heart muscle cells resulting in a net cellular accumulation of Na and secondarily a net cellular loss of K.
This study has reported the detoxification of Thevetia seed meal as well as a quantification of the cardiac glycoside
content in the treated and untreated samples.
While the chemical identity of the inhibitor remained a mystery, the team's data suggested the compound had physiological effects similar to those of a cardiac glycoside
The results revealed that methanolic extract and fractions of plant were rich in alkaloids, tannins, quinones, flavonoids, saponins, coumarins cardiac glycoside
The fruit resembles mango--the kernel contains various toxic principles, the important one is Cerberin, a cardiac glycoside
almost similar in toxicity to digitalis found in Foxglove.
are the most important toxic compounds of the oleander.
We also compared the effect of [TA.sub.AqE] with well-known cardiotonics, isoproterenol (ISO), a [beta]-adrenergic agonist, and ouabain (Ouab), a cardiac glycoside
for the underlying mechanism, efficacy and safety.
Both EIAs were based on the competitive binding of free cardiac glycosides
(ouabain/dihydroouabain) or free mammalian cardenolides (OLF/Dh-OLF) in the sample and bound cardiac glycoside
to a constant amount of the respective antibodies in the EIAs.